Transactive response DNA-binding protein of 43 kDa (TDP-43) regulates RNA processing, including alternative splicing of tau exon 10. Pathological TDP-43 is hyperphosphorylated. However, how do the protein phosphatase(s) (PP) regulate TDP-43 phosphorylation is unclear. Here, we found that both PP1 and PP2A were coimmunoprecipitated with TDP-43. Treatment with calyculin A, but not with okadaic acid, increased TDP-43 phosphorylation at Ser379, Ser403/404, and Ser409/410 in cultured cells. PP1a, PP1b, and PP1c interacted with TDP-43. Overexpression of PP1a and PP1c, but not PP1b, suppressed TDP-43 phosphorylation at Ser403/404 and Ser409/410 and TDP-43-induced tau exon 10 inclusion. These findings suggest that PP1a and PP1c regulate TDP-43 phosphorylation and its function in tau exon 10 inclusion mainly through its phosphorylation at Ser403/404 and Ser409/410.
Transactive response DNA-binding protein of 43 kDa (TDP-43) is a DNA-and RNA-binding protein involved in gene transcription, pre-mRNA splicing, mRNA transport, and mRNA stability [1] . It is the major disease-associated protein involved in the pathogenesis and progression of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions linked to TDP-43 pathology (FTLD-U), also referred to as TDP-43 proteinopathy [2] . Pathological TDP-43 is abnormally post-translationally modified by ubiquitination, acetylation, SUMOylation, truncation, and phosphorylation [2] [3] [4] [5] [6] . Aggregation of hyperphosphorylated TDP-43 is the most consistent and common feature of FTLD and ALS. Thus, abnormal phosphorylation of TDP-43 is believed to mediate its aggregation and toxicity [7] .
Tau is a major neuronal microtubule-associated protein. The main function of tau is to stimulate microtubule assembly and stabilize microtubule network. Tau is hyperphosphorylated and aggregated to form neurofibrillary tangles in the brains of Alzheimer's disease and related to tauopathies [8] . Adult human brain expresses equal levels of 3R-tau and 4R-tau (tau isoforms with three or four microtubule-binding repeats) by alternative splicing of tau exon 10 [9, 10] . Dysregulation of tau exon 10 splicing is known to be associated with sporadic and hereditary tauopathies [11, 12] . We recently found that overexpression of TDP-43 enhances tau exon 10 inclusion and tau mRNA instability [13, 14] . The function of TDP-43 is regulated by phosphorylation [15] , suggesting that factors regulating TDP-43 phosphorylation level could be crucial to Abbreviations ALS, amyotrophic lateral sclerosis; CoIP, coimmunoprecipitation; DMEM, Dulbecco's modified Eagle's medium; FTLD-U, frontotemporal lobar degeneration with ubiquitin; HA, haemagglutinin; PP, protein phosphatase(s); TBS, tris-buffered saline; TDP-43, transactive response DNA-binding protein of 43 kDa. neurodegeneration involved in tauopathies and TDP-43 proteinopathy. However, it is unclear which protein phosphatase (PP) dephosphorylates and regulates TDP-43 function in the brain. In the present study, we found that PP1 is a TDP-43 phosphatase, and that overexpression of PP1a or PP1c suppresses TDP-43 phosphorylation and tau exon 10 inclusion.
Materials and methods
Plasmids, antibodies, and other reagents pCI/TDP-43 tagged with haemagglutinin (HA) was prepared as described before [14] . pcDNA3.1/PP1a, b, and c tagged with Myc and His were generated by PCR amplification from pEGFP-C1/PP1a, b, and c (a kindly gift from Dr. Laura Trinkle-Mulcahy, University of Ottwa, Canada) and confirmed by DNA sequence analysis. Mutations of Ser409/410 to Ala (TDP-43 2A ) or to Asp (TDP-43 2D ) was generated by using PrimeSTAR TM HS DNA Polymerase (Takara Bio Inc., Otsu, Shiga, Japan). pCI/SI9-LI10 containing a tau mini-gene, SI9-LI10, comprising tau exons 9, 10, 11, part of intron 9, and all of intron 10 was described previously [16] . Monoclonal and polyclonal anti-HA antibodies were bought from Sigma (Sigma, St Loius, MO, USA). Polyclonal anti-TDP-43 for western blots was from Cell Signaling Technology (Danvers, MA, USA), for immunocytochemistry was from Proteintech Group Inc (Chicago, IL, USA). Monoclonal anti-myc and anti-PP1 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-pS379-TDP-43, anti-pS403/404-TDP-43, and anti-pS409/410-TDP-43 were made by Abmart Company (Shanghai, China). Protein G beads and the ECL kit were from Thermo Fisher Scientific (Rockford, IL, USA). Peroxidase-conjugated anti-mouse and anti-rabbit IgG were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA, USA); Alexa 488-conjugated goat antirabbit IgG, Alexa 555-conjugated goat anti-mouse IgG, and TOPRO-3 iodide (642/661) were from Invitrogen (Invitrogen, Carlsbad, CA, USA).
Cell culture and transfection
HEK-293FT and HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Invitrogen) at 37°C (5% CO 2 ). All transfections were performed with FuGENE HD (Promega, Madison, WI, USA) or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Immunoprecipitation and Coimmunoprecipitation
Transactive response DNA-binding protein of 43 kDa tagged with HA was expressed in HEK-293FT cells for 46 h and treated with 50 nM calyculin A (Cal A) or okadaic acid (OA) for 2 h. The cells were washed twice with PBS, and lysed with lysate buffer, containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, 1 mM Na 3 VO 4 , 50 mM NaF, 2 mM EDTA, 1 mM PMSF, and 10 lgÁmL À1 of each of aprotinin, leupeptin, and pepstatin on ice for 20 min. After centrifugation at 15 000 9 g for 5 min, extract was incubated with protein G beads precoupled with monoclonal anti-HA overnight at 4°C. The beads were washed with lysis buffer twice and with Tris-buffered saline (TBS) twice. The bound proteins were eluted by boiling in 2 9 Laemmli sample buffer (125 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 10% 2-mercaptoethanol, and 0.004% bromphenol blue). Three PP1 isoforms tagged with Myc or TDP-43 tagged with HA were transfected into HEK-293FT cells and proceeded to coimmunoprecipitation (CoIP). CoIP was carried out in a way similar to the immunoprecipitation described above except that the cells were lysed by sonication in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM Na 3 VO 4 , 50 mM NaF, 2 mM EDTA, 1 mM PMSF, and 10 lgÁmL À1 of each of aprotinin, leupeptin, and pepstatin), then centrifuged at 15 000 9 g for 5 min to obtain the extract.
Immunofluorescence
HeLa cells were plated onto coverslips in 24-well plates 1 day before transfection. The cells were transfected with pCI/ TDP-43 and pcDNA3.1/PP1a, b, or c. Two days after transfection, the cells were washed with PBS and fixed with 4% paraformaldehyde in PBS for 30 min at room temperature. After washing with PBS, the cells were blocked with 10% goat serum in 0.2% Triton X-100/PBS for 2 h at 37°C, and then incubated with monoclonal anti-myc (1 : 200) and polyclonal anti-HA (1 : 400) overnight at 4°C. The cells were washed and incubated for 2 h with secondary antibodies (Alexa 488-conjugated goat anti-mouse IgG and Alexa 555-conjugated goat anti-rabbit IgG, 1 : 500) plus TO-PRO-3 iodide (5 lgÁmL
À1
) at room temperature. After washing with PBS, the cells were mounted with antifade mounting media (Roche, Diagnotics, USA), and observed with a Nikon TCS-SP2 laser-scanning confocal microscope.
Western blots
Proteins were separated by SDS/PAGE and electrically blotted on polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% fat-free milk in TBS (for 30 min), and then incubated with primary antibody in 5% fat-free milk and 0.5% NaN 3 in TBS overnight at room temperature. After washing three times with TBST (TBS with 0.05% Tween 20), the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies for 2 h. Following three washes with TBST, the membrane was incubated with ECL for 1 min, and then exposed to X-ray films (Kodak, Rochester, NY, USA).
Quantitation of tau Exon 10 Splicing by Reverse Transcription-PCR (RT-PCR)
Total cellular RNA was extracted from cultured cells by using the RNeasy mini kit (Qiagen, GmbH, Germany) according to the manufacturer's instruction. One microgram of total RNA was used for first-strand cDNA synthesis with oligo-(dT) 18 by using the Omniscript reverse transcription kit (Qiagen). PCR was performed by using Prime STAR TM HS DNA Polymerase (Takara Bio Inc., Otsu, Shiga, Japan) with forward primer 5 0 -GGTGTCC ACTCCCAGTTCAA-3 0 and reverse primer 5 0 -CCCTGGT TTATG ATGGATGTTGCCTAATGAG-3 0 to measure the alternative splicing of tau exon 10. The conditions of PCR were: 98°C for 5 min, 98°C for 10 s, 68°C for 40 s for 30 cycles, and then 68°C 10 min for extension. The PCR products were resolved on 1.5% agarose gels, visualized by ethidium bromide staining and quantitated using the Molecular Imager system (Bio-Rad).
Statistical analysis
The data were presented as mean AE SD. Data points were compared by the unpaired two-tailed Student's t test for comparison of two groups and by one-way ANOVA for multiple group comparison. A value of P < 0.05 was considered statistically significant.
Results

PP1 interacts with and dephosphorylates TDP-43
To identify TDP-43 phosphatase(s), we first investigated which of the major brain PPs could interact with TDP-43 using coimmunoprecipitation assay. We overexpressed TDP-43 tagged with HA in HEK-293FT cells, immunoprecipitated TDP-43 with anti-HA, and analyzed the coimmunoprecipitated phosphatases by western blots. We found that PP1 and PP2A were coimmunoprecipitated with TDP-43 and that coimmunoprecipitation of PP1 with TDP-43 was more robust than that of PP2A (Fig. 1A) . PP2B or PP5 was not coimmunoprecipitated with TDP-43 (Fig. 1A) . These results suggest that TDP-43 interacts with PP1 and PP2A. In FTLD-U and ALS brains, TDP-43 is phosphorylated at several phosphorylation sites, including Ser379, Ser403/404, and Ser409/410 [7] . To learn the role of PP1 and/or PP2A in TDP-43 phosphorylation, we chose okadaic acid (OA) and calyculin A (Cal A) as selective inhibitors for the study. PP1 and PP2A show different sensitivity to OA and Cal A. The IC 50 (half maximal inhibitory concentration) of OA is 1 nM toward PP2A and 10-to 100-fold higher concentration toward PP1 [17, 18] . However, Cal A inhibits PP1 and PP2A with similar potencies (with IC 50 values of 0.5-2 nM) [18, 19] . We overexpressed TDP-43 in HEK-293FT cells for 46 h, and then treated the cells with 50 nM OA or 50 nM CalA for 2 h. We then immunoprecipitated TDP-43 with anti-HA and analyzed its phosphorylation levels by western blots developed with site-specific and phosphorylation-dependent anti-TDP-43 antibodies. We found that the phosphorylation levels of TDP-43 at Ser379, Ser403/404, and Ser409/ 410 were significantly increased in cells treated with Cal A (that inhibits both PP1 and PP2A at the concentration used), but not with OA (i.e., known to inhibit mainly PP2A at the concentration used) (Fig. 1B,  C) . These results suggest that PP1, but not PP2A, probably serves as a TDP-43 phosphatase. TDP-43 interacts with PP1a, b, and c There are three PP1 isoforms, PP1a, PP1b, and PP1c [20, 21] , in the mammalian brain. To study the interaction between PP1 isoforms and TDP-43, we expressed three PP1 isoforms tagged with Myc in HEK-293FT cells. Three PP1 isoforms were then immunoprecipitated with monoclonal anti-Myc and analyzed by western blots. We found that TDP-43 was coimmunoprecipitated with PP1a, PP1b, and PP1c ( Fig. 2A) , suggesting that these three PP1 isoforms could all interact with TDP-43.
To learn whether TDP-43 colocalized with PP1 isoforms, we coexpressed TDP-43 with PP1a, PP1b, or PP1c in HeLa cells and examined their localizations by confocal microscopy after immunofluorescent staining with polyclonal anti-HA (TDP-43) and monoclonal anti-Myc (PP1). We found that TDP-43 localized extensively in the nucleus but PP1a, PP1b, and PP1c located mainly in nucleus (Fig. 2B) . Double immunofluorescence indicated that TDP-43 colocalized with PP1a, PP1b, and, to a smaller extent, with PP1c in the nucleus (Fig. 2B ).
PP1a and PP1c dephosphorylate TDP-43 at Ser379, Ser403/404, and Ser409/410
Since all three major PP1 isoforms can interact with TDP-43, we investigated whether these PP1 isoforms dephosphorylate TDP-43 in an isoform-specific manner. We coexpressed HA-tagged TDP-43 with PP1a, PP1b, or PP1c in HEK-293FT cells, and then analyzed TDP-43 phosphorylation level by western blots developed with antibodies against Ser379, Ser403/404, or Ser409/410 after immunoprecipitation of TDP-43 with anti-HA. We found that compared with control vector transfection, expression of PP1a and, to a less extent, PP1c, but not PP1b, led to marked decreases in the phosphorylation level of TDP-43 (Fig. 3A,B) . While PP1a robustly dephosphorylated TDP-43 at all the three sites, PP1c was effective in dephosphorylation at Ser403/404 and Ser409/410, but not at Ser379. These results suggest that PP1a and PP1c act as TDP-43 phosphatases.
To study the role of PP1 in subcellular distribution of TDP-43, we overexpressed PP1a in HeLa cells and immunostained the cells with anti-TDP-43 and antiPP1a. We found that TDP-43 was located in the nucleus of the cells with or without coexpression of PP1a (Fig. 3C) , suggesting that overexpression of PP1 did not affect the subcellular localization of TDP-43.
PP1a and PP1c suppress TDP-43-promoted tau exon 10 inclusion
We recently found that TDP-43 promotes tau exon 10 inclusion [14] . To determine whether PP1 affects TDP-43's activity in tau exon 10 splicing, we coexpressed SI9-LI10 mini-tau gene, pCI/SI9-LI10, with TDP-43 and PP1a, PP1b, or PP1c in HEK-293FT cells and analyzed the splicing products of tau exon 10 by RT-PCR. We found that TDP-43 overexpression enhanced tau exon 10 inclusion (Fig. 4A,B) . Coexpression of PP1a or PP1c suppressed TDP-43-promoted tau exon 10 inclusion (Fig. 4A,B) . However, coexpression of PP1b did not affect TDP-43-mediated tau exon 10 inclusion significantly (Fig. 4A,B) . These results are consistent to the selective TDP-43 dephosphorylation with various PP1 isoforms and suggest that PP1a and PP1c, but not PP1b, regulate TDP-43 function in tau exon 10 splicing.
Phosphorylation of Ser409/410 is a consistent feature of all sporadic and familial forms of TDP-43 proteinopathies [22] . To learn the role of phosphorylation of TDP-43 at Ser409/410 in tau exon 10 splicing, we mutated Ser409/410 to Ala (TDP-43 2A ) or Asp (TDP-43 2D ) to prevent or mimic phosphorylation and overexpressed them in the cells transfected with pCI/SI9-LI10. We determined the expression of TDP-43 by western blots and splicing products of tau exon 10 by RT-PCR (Fig. 4C) . Consistently, we found TDP-43 enhanced tau exon 10 inclusion (Fig. 4C,D) . However, both TDP-43 2A and TDP-43 2D failed to enhance tau exon 10 inclusion (Fig. 4C,D) .
Overexpression of PP1a suppressed tau exon 10 inclusion by TDP-43 (Fig. 4C,D) . Surprisingly, regardless of the coexpression of TDP-43 or its mutants, the ratios of inclusion/exclusion of tau exon 10 in the cells transfected with PP1a were similar (Fig. 4D) . These results suggest that PP1a not only suppresses TDP-43 but also may suppress other splicing factors, including endogenous TDP-43, and promoting tau exon 10 inclusion. The ratios of tau exon 10 inclusion and exclusion were calculated and are presented as mean AE SD (n = 3). **, P < 0.01, ***, P < 0.001.
Discussion
Abnormal phosphorylation of TDP-43 may be associated with its aggregation and toxicity [7] . In the present study, we found that PP1 interacted with TDP-43. Inhibition of PP1 elevated TDP-43 phosphorylation at Ser379, Ser403/404, and Ser409/410. Three PP1 isoforms all interacted with TDP-43 and colocalized with TDP-43 in the nucleus. However, overexpression of PP1a, or PP1c, but not PP1b, suppressed TDP-43 phosphorylation and activity in tau exon 10 inclusion. PP1 isoforms dephosphorylated TDP-43 site specifically. Overexpression of PP1a effectively dephosphorylated TDP-43 at Ser379, Ser403/404, and Ser409/410, but PP1c overexpression failed to dephosphorylate TDP-43 at Ser379. PP1a overexpression suppressed TDP-43-promoted-tau exon 10 inclusion. However, both TDP-43 2A and TDP-43 2D failed to enhance tau exon 10 inclusion. Taken together, our studies suggest that PP1a and PP1c are TDP-43 phosphatases and regulate its function in tau exon 10 splicing mainly through its phosphorylation at Ser403/404 and Ser409/410 and apparently not through phosphorylation at Ser379.
Transactive response DNA-binding protein of 43 kDa is deposited as cytoplasmic and intranuclear inclusions in the brains of subjects with FTLD-U and ALS. Phosphorylated TDP-43 is a major component of the inclusions. Abnormal phosphorylation of TDP-43 is a critical step in the pathogenesis of FTLD-U and ALS [7] . There are 56 Ser/Thr residues within the human TDP-43 molecule. Almost all Ser and Thr residues in the C terminus are able to be phosphorylated in vitro [15] . Up to date, 19 Ser/Thr phosphorylation sites in the aggregated TDP-43 from ALS and FTLD-U have been identified [7, 23] . Phosphorylation of S409/410 of TDP-43 is a highly consistent feature in the pathologic inclusions in the whole spectrum of sporadic and familial forms of TDP-43 proteinopathies [22] . Phosphorylation of TDP-43 by casein kinase 1e promotes oligomerization and enhances toxicity in vivo [24] . High active casein kinase 1d was previously shown to phosphorylate TDP-43, triggering its mislocalization and accumulation in the cytoplasm from the nucleus [25] . In the present study, we found that overexpression of PP1a and PP1c suppresses TDP-43 phosphorylation at Ser403/404 and Ser409/410 effectively. Inhibition of PP1 resulted in an increase in TDP-43 phosphorylation at these sites. Thus, PP1, specifically isoforms a and c, serves as a TDP-43 phosphatase.
PP1 is a major eukaryotic protein serine/threonine phosphatase that regulates an enormous variety of cellular functions. The four mammalian PP1 gene products initially identified were designated PP1a, PP1b (also termed PP1d), PP1c1, and PP1c2, the latter two arising through alternative splicing [26] [27] [28] . They share more than 90% homology. PP1 binds to its target through conserved binding motifs, such as RVxF, and SILK [29] . However, TDP-43 does not contain these motifs, suggesting that PP1 may target TDP-43 through regulatory subunits, which remains elusive.
In addition to PP1, PP2B (calcineurin) was reported to interact with TDP-43 by yeast two-hybrid screen and dephosphorylate it in vitro [30] . Inhibition of PP2B by FK506 results in accumulation of phospho-TDP-43 in cultured cells [30] . In the present study, we found that PP2B was not coimmunoprecipitated with TDP-43, suggesting that the interaction of PP2B with TDP-43 might be transient. It is well known that PP2B dephosphorylates PP1 inhibitor, resulting in enhancing PP1 activity [31] . Thus, in addition to the direct activity on TDP-43 as previously reported [30] , we speculate that PP2B could dephosphorylate TDP-43 indirectly through PP1.
Transactive response DNA-binding protein of 43 kDa plays critical roles in RNA processing. We recently reported that TDP-43 promotes tau mRNA instability and tau exon 10 inclusion [13, 14] . Here, we found that overexpression of PP1a and PP1c suppressed TDP-43 phosphorylation and its function in tau exon 10 inclusion. However, both TDP-43 2A and TDP-43 2D failed to promote tau exon 10 inclusion, suggesting that Ser409/410 phosphorylation regulates its function complicatedly. TDP-43 2A was not able to promote tau exon 10 inclusion, suggesting phosphorylation of TDP-43 at Ser409/410 may be required for TDP-43's function. It is known that phosphorylation promotes TDP-43 aggregation in the cytoplasm [25] . In the brains of FTLD-U and ALS, phosphorylated TDP-43 is a major component of the cytoplasmic inclusions [7, 22] . Thus, mimic-phosphorylation of TDP-43 at Ser409/410, TDP-43 2D , may lead to the aggregation, resulting in TDP-43 unavailable for tau exon 10 splicing. It is well known that PP1 activity is reduced in the brains of people with Alzheimer's disease [32] . Thus, we presume that reduced PP1 activity may cause TDP-43 phosphorylation and dysregulate tau exon 10 splicing and tau expression, contributing to tau pathogenesis in AD, which remains to be determined by specific downregulation of PP1 with the PP1-specific inhibitor [33] . 
